Vol. 24/No. 6

Cancer screenings rapidly decreased during the COVID-19 pandemic as health care practices considered not urgent came to a halt.

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Roadblocks such as PARP inhibitor resistance have resulted in an unmet need and uncertain optimal identification concerning patients who would elicit the most benefit from homologous recombination deficiency–directed therapies.

The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.

Robert L. Coleman, MD, FACOG, FACS, the 2020 Giants of Cancer Care® award winner in gynecologic malignancies, notes that despite the great progress in the past decade, more work is needed to personalize and refine approaches to care.

As the great baseball catcher and philosopher Yogi Berra noted, “When you come to a fork in the road, take it.” And in my opinion, we surely are at that juncture with human papillomavirus vaccination.